DDInter596 DDInter904
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Doxorubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) upregulates {v} (Gene) MEGF8
MEGF8 {u} (Gene) is upregulated by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topoisomerase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) CBR3
CBR3 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) downregulates {v} (Gene) CHD1
CHD1 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Haemorrhage {u} (Side Effect) is caused by {v} (Compound) Idarubicin
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Doxorubicin (Compound) resembles Idarubicin (Compound)
Doxorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Idarubicin (Compound)
Doxorubicin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Idarubicin (Compound)
Doxorubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Doxorubicin (Compound) upregulates MEGF8 (Gene) and MEGF8 (Gene) is upregulated by Idarubicin (Compound)
Doxorubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class) and Topoisomerase Inhibitors (Pharmacologic Class) includes Idarubicin (Compound)
Doxorubicin (Compound) binds CBR3 (Gene) and Doxorubicin (Compound) downregulates CBR3 (Gene) and CBR3 (Gene) is downregulated by Idarubicin (Compound)
Doxorubicin (Compound) downregulates CHD1 (Gene) and CHD1 (Gene) is downregulated by Idarubicin (Compound)
Doxorubicin (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Doxorubicin (Compound) binds TOP2A (Gene) and Doxorubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Idarubicin (Compound) and TOP2A (Gene) is downregulated by Idarubicin (Compound)